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ORIGINAL ARTICLE
TIFA, an inflammatory signaling adaptor, is tumor
suppressive for liver cancer
W Shen1, A Chang1, J Wang1, W Zhou1, R Gao1, J Li1, Y Xu1, X Luo1, R Xiang1, N Luo1 and DG Stupack2
TIFA (TNF receptor associated factor (TRAF)-interacting protein with a Forkhead-associated (FHA) domain), also called T2BP, was first
identified using a yeast two-hybrid screening. TIFA contains a FHA domain, which directly binds phosphothreonine and
phosphoserine, and a consensus TRAF6-binding motif. TIFA-mediated oligomerization and poly-ubiquitinylation of TRAF6 mediates
signaling downstream of the Tumor necrosis factor alpha receptor 1 (TNFaR-I) and interleukin-1/Toll-like receptor 4 (TLR4) pathways.
Examining TIFA expression in hepatocellular carcinoma (HCC) tissues microarrays, we noted marked decreases TIFA reactivity in tumor
versus control samples. In agreement, we found that HCC cell lines show reduced TIFA expression levels versus normal liver controls.
Reconstituting TIFA expression in HCC cell lines promoted two independent apoptosis signaling pathways: the induction of p53 and
cell cycle arrest, and the activation of caspase-8 and caspase-3. In contrast, the expression of a non-oligomerizing mutant of TIFA
impacted cells minimally, and suppression of TIFA expression protected cells from apoptosis. Mice bearing TIFA overexpression
hepatocellular xenografts develop smaller tumors versus TIFA mutant tumors; terminal deoxynucleotidyl transferase dUTP nick end
labeling staining demonstrates increased cell apoptosis, and decreased proliferation, reflecting cell cycle arrest. Interestingly, p53 has
a greater role in decreased proliferation than cell death, as it appeared dispensable for TIFA-induced cell killing. The findings
demonstrate a novel suppressive role of TIFA in HCC progression via promotion of cell death independent of p53.
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INTRODUCTION
Chronic liver inflammation is associated with increased incidence
of liver cancer. Hepatocellular carcinoma (HCC), the most common
liver cancer, is an end product of chronic liver disease typically
requiring decades to evolve. HCC is the fifth most common cancer
worldwide, with a doubling incidence in the United States alone
during the last two decades.
An increased incidence of inflammatory mediators, such as
ATF4,1,2 TLR4,3,4 TREM-1,5,6 have been linked to the development
of HCC; other proteins, such as TIFA (TRAF-interacting protein with
a Forkhead-associated (FHA) domain), are upregulated in response
to hypoxia or other acute stress.7 The most frequent cause for
chronic hepatic inflammation in humans is infection with hepatitis
B virus or hepatitis C virus, which currently persist in approxi-
mately 500 million people worldwide, and fosters an increasing
HCC patient population. Effective means to eradicate these
chronic viral infections have been elusive, although new
treatments for hepatitis C virus are poised to make a significant
impact if economic barriers can be overcome.
Analysis of fundamental inflammatory signaling pathways may
therefore reveal targets or markers to identify and treat patients
with chronic liver inflammation, particularly those predictive of HCC.
TIFA, also called T2BP, was identified as a TRAF6-interacting protein
in a yeast two-hybrid screen,8 but may also bind TRAF2.9 In addition
to the FHA domain, a phosphothreonine and phosphoserine-
binding motif,10 TIFA contains a consensus TRAF6-binding
motif.11,12 Elevated TIFA expression activates nuclear factor (NF)-
κB and c-JUN N-terminal kinase in a manner dependent on TRAF6,13
and links TRAF6 to NF-κB in the interleukin-1/TLR4 pathway.8 TIFA is
increased after cell stress such as hypoxia; the increase in TIFA level
appears to feed forward into TLR4/MyD88-dependent signaling,
leading to NF-κB activation and HMGB1 release.7 The data are
consistent with a pro-tumorigenic role for TIFA.
Here, we studied the role of TIFA in normal liver and HCC.
Unexpectedly, we find that TIFA expression is suppressed
during tumor progression, in contrast to other inflammatory
mediators.2,4,5 In agreement, TIFA reconstitution induced the
expression of p53, promoting apoptosis while suppressing
proliferation among surviving cells. The studies implicate TIFA as
a previously unappreciated suppressor of liver carcinogenesis via
p53-dependent and -independent mechanisms, and provide
insight into a vulnerability of HCC.
RESULTS
TIFA is decreased in HCC
The expression of TIFA was examined in microarrays containing
liver biopsies from 150 patients (110 HCC samples and 40 normal
samples). As shown (Figure 1a), a relatively robust expression of
TIFA was detectable in normal liver tissues, whereas in contrast,
TIFA expression was weakly detected in frank carcinoma. TIFA loss
was notable even in early-stage disease (Figure 1b).
As TIFA has a role in promoting inflammation, which fosters
HCC, this result was somewhat unexpected. Therefore, we also
examined TIFA protein data presented in the Human Protein Atlas
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(HPA) (www.proteinatlas.org). Despite using a different antibody
to detect TIFA, HPA data were in agreement with our observations;
the detection of TIFA was decreased in liver cancer relative to
controls (Supplementary Table 1).
TIFA expression is suppressed in HCC tumor cell lines
We investigated whether the observations in clinical samples were
represented in tumor cell lines. The mRNA level of TIFA was found
to be decreased in HCC cell lines relative to normal liver cell line
(Figure 2a, inset). Immunoblot analysis of TIFA protein levels
supported the quantitative PCR results, suggesting that TIFA was
in fact decreased in the cell lines (Figure 2a). Therefore, the cell
lines appeared suitable to use as a model to determine the impact
of TIFA on HCC biology.
To investigate the functional role of TIFA in HCC, we
reconstituted either wild-type (WT) TIFA, or an oligomerization
defective (TRAF6-binding mutant, TIFAΔ6) (Figure 2b) into HCC
tumor lines. We noted some loss of cells in the TIFA expression
groups. Checking more carefully, we noted cell death within the
HCC tumor lines SK-Hep-1 (Figures 2c and d) following expression
of TIFA. However, expression of TIFAΔ6, which does not bind
TRAF6, did not induce cell death. As reported by others,
coprecipitation studies supported a selective and constitutive
interaction of TIFA with TRAF67 (unpublished data), but not TRAF2,
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Figure 1. TIFA protein abundance is decreased in HCC tissue. (a) The representative image of TIFA staining in human tissue microarrays
(including 110 HCC samples and 50 normal samples). Scar bar, 100 μm. (b) The relationship of TIFA-positive cells with tissue status or HCC
clinical stage. Each point represents one sample and the middle line represents the mean value. Data are shown as the mean± s.e.m. The
number of samples and the mean values of each group are listed below the x axis. (P-value was determined by Student’s t-test).
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a component of (apoptotic) complex II. Nonetheless, apoptosis
was suggested by Annexin-V staining, and was further supported
by detection of increased levels of the cleaved form of caspase-3.
Similar results were observed with the HepG2 cell line (Figure 2d),
supporting the notion that TIFA expression could promote
apoptosis among HCC.
TIFA reconstitution fosters apoptosis in vivo
To determine if the pro-apoptotic effects of TIFA were maintained
in vivo, we next performed tumor xenograft studies in nude mice.
Consistent with the results obtained using in vitro assays, a
significantly diminished tumor size was observed selectively
among tumors from SK-Hep1 TIFA-expressing cells, relative to
controls or SK-Hep1 TIFAΔ6-expressing cells (Figure 3a). The
harvested TIFA-expressing tumors exhibited TIFA protein levels
similar to that seen in normal liver (Figure 3b). Concordant with
the decreased tumor size, we observed increased terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining within the tumor proper (Figure 3c). By contrast, the
control and TIFAΔ6-expressing tumors grew similarly, and
displayed similar levels of TUNEL staining; roughly one-fifth of
that seen in TIFA-positive tumors. Thus, TIFA expression was
deleterious to HCC in vivo as well as in vitro. Mechanistically, this
was at least partly due to apoptosis.
TIFA promotes cell cycle arrest
We also evaluated proliferation via an assessment of Ki-67 staining
to control for cell proliferation as an alternative explanation for the
disparity in tumor size. Unexpectedly, TIFA expression was
associated with significantly decreased Ki-67 reactivity in tumors,
indicating that apoptosis may not act alone to limit tumor size
(Figure 4a). Evaluating growth in vitro, we confirmed that TIFA
expression led to differences of both overall proliferation in
SK-Hep1 and HepG2 cells (Figure 4b), most particularly with long-
term culture proliferation. The difference in net proliferation did
not appear to be explainable by cell loss because of apoptosis,
and indeed there was a concomitant increase in Myt1/CDC2 as
well as p21, with a decrease in cyclin E2 (Figure 4c). Moreover, it
was accompanied by an increase in the G0/G1 population of cells
(Figure 4d). Conversely, suppression of TIFA via short hairpin RNA
(shRNA)-mediated silencing promoted proliferation (Figure 4e).
The collective evidence suggested that TIFA expression acted to
suppress tumor progression via more than one mechanism.
In agreement with this, a parallel Pathscan Array study showed
that, relative to controls, an enhanced level of c-JUN N-terminal
kinase and phospho-p53 was noted in TIFA-expressing cells
(unpublished observations). As p53 activation fosters cell cycle
arrest and apoptosis,14 and microRNA that targets TIFA can
downregulate p53 and Bak, we next evaluated a role for p53
downstream of TIFA in the HCC cells. Immunoblot analysis of p53
protein expression revealed that TIFA expression in either Sk-Hep1
or HepG2 lead to an enhancement of both overall p53 levels
as well as levels of phosphorylated p53 (Ser 15; Figure 5a).
The observation was consistent with both increased apoptosis
observed and cell cycle arrest.
TIFA acts via p53-dependent and -independent mechanisms
To further test whether p53 may be a key element downstream of
TIFA, we next used an shRNA approach to stably suppress p53
expression among cells reconstituted for TIFA expression. Perhaps
surprisingly, the loss of p53 did not rescue apoptosis induced by
TIFA expression (Figure 5b). However, amelioration of the cell
cycle block and proliferation was observed (Figure 5c), suggesting
that p53, while required for cell cycle arrest, was not essential for
apoptosis in this system. Concordant with this, low levels of
p21 induction (relative to controls) were detected in the p53
suppressed cells (Figure 5d).
We next examined the mechanism by which these cells undergo
apoptosis via an examination of the initiator and downstream
caspases. In addition to the executioner caspase-3, we detected
cleavage of procaspase-8 (but not 9) associated with its maturation
and activation. The addition of caspase inhibitors blocked caspase-8
cleavage and rescued HCC cell apoptosis (Figure 5e), but did not
significantly impact the cell cycle (Figure 5f). The results implicate a
p53-independent mechanism by which TIFA induces cell death, and
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Figure 2. Ectopic expression of TIFA promotes apoptosis in
hepatoma cells. (a) Real-time PCR and western blot were performed
to detect the expression of TIFA in normal liver cell and HCC cell
lines. (b) Overview of TIFA structure. TIFA contains three domains
(N, FHA, C). The E178* mutant (GAA/TGA) lacks the last six amino
acids that interact with TRAF6 (TIFAΔ6). (c) Flow cytometry showing
the percentage of dead cells detected by PI-Annexin V double
staining in TIFA or TIFAΔ6 cells. A representative experiment of three
is shown. (d) Statistical results of the percentage of apoptotic cells
are shown. The immunoblotting shows relative TIFA expression as
well as the expression of cleaved caspase-3. β-Actin is included as a
loading control.
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a p53-dependent mechanism of cell cycle arrest (Figure 5g). As
430% of HCC may lose p53 function, the direct activation of caspase
activity may represent a key mechanism to limit tumorigenesis.
DISCUSSION
HCC is the third most common cause for cancer-related death
worldwide.15 In some African and Asian countries, HCC has
become the most prevalent cause for cancer-related death.16
Considering the effort invested, the clinical success to pharmaco-
logically treating HCC patients has been limited, although the
development of antivirals, such as Sofosbuvir, is promising.
A better understanding of tumorigenesis, and the subsequent
analysis and identification of new targets or predictive markers for
HCC therapy is timely and, for many, urgent.
The roles shown for here for TIFA are unexpected. Most
inflammatory mediators tend to promote HCC development. TIFA,
by contrast, is not observed to be upregulated in HCC. In fact, this
is independent of tumor stage, supporting the notion that loss or
suppression of TIFA may be an early step toward tumor
development. Indeed, TIFA can foster HCC apoptosis, and loss of
apoptotic sensitivity is a hallmark of cancer.17
Caspase-1 and 2, in particular, are implicated in inflam-
mation,18–20 and caspase inhibitors targeting these are in clinical
development.21,22 Suppression of inflammation may, however,
carry an oncogenic risk, if early events fostering tumor progression
are already in process, and the caspase-dependent killing we
observe is prevented. This may be particularly important in the
generation of the p53-compromised subgroup of HCC (30–40%)
where caspase activity may be a final barrier to malignancy.
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Figure 3. Ectopic expression of TIFA promotes cell apoptosis in vivo. (a) Tumor growth curve of control, TIFA, and TIFAΔ6 tumors harvested
from the flank of NOD/SCID mice. Several tumors separated from each group are shown (inset). (b) Immunoblot analysis of the expression of
TIFA in reconstituted and control SK-Hep1 cells relative to normal liver. (c) Bar graph shows the statistical results of TUNEL staining illustrated
in panel c. Scar bar, 100 μm. *Po0.05, **Po0.01, ***Po0.001 compared with control by Student’s t-test. (d) Representative images showing
TUNEL staining of xenografted tumor tissue from each group (control, TIFA, TIFAΔ6).
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TIFA has been associated with other signaling pathways, most
notably, the NF-κB pathway,9,11,13 which promotes oncogenesis
and tumor progression via nuclear translocation and activation of
target genes. TIFA expression can also promote activation of the
mitogen-activated protein kinase, extracellular signal-regulated
kinase, c-JUN N-terminal kinase and p38. Activation of c-JUN
N-terminal kinase and p38 in particular can trigger downstream
cascades that lead to inflammation, differentiation or cell
death.23–28 Although we observed some activation of these
pathways in both the SK-Hep1 and the HepG2 cell lines following
TIFA expression (unpublished observations), the patterns and role
of these activations were not simple or clear, and further
manipulation of these pathways is ongoing to determine if they
are required or even relevant to the processes described here.
The studies here present two unexpected findings. The first is that
the protein TIFA, which fosters NF-κB signaling,13 can induce
apoptosis and thus may have a novel role as a regulator of HCC
development by fostering removal of transformed cells. This function
of TIFA requires the six C-terminal amino-acid residues that bind
TRAF6. The second is that this activity proceeds concordant with
p53-mediated induction of cell cycle arrest, but occurs even when
p53 expression is suppressed. We propose that the oligomerization-
competent form of TIFA is poised to promote caspase-dependent
cell death as a counterpoint to ongoing inflammation. Caution may
be warranted in the development of caspase inhibitors as a
mechanism of combating chronic liver inflammation.
MATERIALS AND METHODS
Vector construction
The complementary DNA of human TIFA was cloned by reverse
transcription PCR using total RNA from L02 cells, and using the specific
primer pairs for TIFA (forward: 5′-CGGGATCCATGACCAGTTTTGAAGATG
CTG-3′, reverse: 5′-CGGAATTCTCATGACTCATTTTCATCCATTTC-3′). The
amplified fragments were first ligated into pCMV-Tag 2B labeled with
FLAG tag and then cloned using the primer pairs for Flag-TIFA (forward:
5′-GCTCTAGAGCCACCATGGATTACAAGGAT-3′, reverse: 5′-CGACGCGTTCAT
GTCGGAGAACTGCTTTG-3′). The amplified fragments were finally ligated
into pLV-EF1α-MCS-IRES-Bsd (cat. #cDNA- pLV 03, Biosettia Inc., San Diego,
CA, USA) expression vector. The mutant TIFA fragments were cloned from
the overexpression vector with using the primer pairs for TIFAΔ6. The
amplified fragments were also finally ligated into pLV-EF1α-MCS-IRES-Bsd
(cat. #cDNA- pLV 03, Biosettia Inc.) expression vector. The shRNA sequence
for silencing mice TIFA gene was searched and blasted using RNAi designer
from the Invitrogen website (https://rnaidesigner.invitrogen.com/rnaiex
press/index.jsp). ShRNA targeting human TIFA and scrambled control
sequence were designed and chemically synthesized as TIFA–shRNA1
(5′-AAAAGGTCAGATTCGGAGAGTATCATTGGATCCAATGATACTCTCCGAATC
TGACC-3′) TIFA–shRNA 2 (5′-AAAAGGTGAAATTTGGCCGAAATTCTTGGAT
CCAAGAATTTCGGCCAAATTTCACC-3′) and TIFA-shRNA3 (5′-AAAACCAAG
ATCACTCTTGCAAGAATTGGATCCAATTCTTGCAAGAGTGATCTTGG-3′). The
control, TIFA-sc, was 5′-AAAAGCTACACTATCGAGCAATTTTGGATCCAAAA
TTGCTCGATAGTGTAGC-3′. The palindromic DNA oligos were annealed to
each other to form a double-strand oligo and ligated to the linearized
pLV-H1-EF1α-puro (cat. #SORT-B19, Biosettia Inc.) vector to generate circled
pLV-EF1α-shRNA-TIFA-Puro.
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Figure 4. Ectopic expression of TIFA inhibits cell proliferation in vitro and in vivo. (a) The images show the immunohistochemistry staining of
FLAG, TIFA and Ki-67 in tumor tissues separated from xenografted NOD/SCID mice subcutaneously injected with control, TIFA or TIFAΔ6
SK-Hep1 cells. Scar bar, 100 μm. (b) The cell growth of two cell lines (SK-Hep1 cell and HepG2 cell) were analyzed at 0, 24, 48, 60 and 72 h after
cell seeding. Cell lysates were immunoblotted with antibodies detecting the ki-67 using specific anti-Ki-67 antibody are shown in the inset.
β-Actin was used as a loading control. (c) Immunoblot showing cell cycle-related protein expression in TIFA or TIFAΔ6 cells. β-Actin is included
as a loading control. (d) Stacked bar graph showing the result of three separated experiments of cell cycle analysis via 7-aminoactinomycin D
(7-AAD)/5-bromo-2-deoxyuridine (BrdU)-FITC double staining analyzed by flow cytometry. (e) Lentiviral expression of shRNA to TIFA was
evaluated by immunoblotting for effect in SK-HEP1 cells (right panel), and for effect on cell proliferation (left panel).
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Cell culture
Human normal liver cell line, L02, was obtained from the Chinese Academy
of Sciences (Beijing, China). L02 cell line was maintained in RPMI-1640
media supplemented with 10% fetal bovine serum, 100 U/ml penicillin/
streptomycin. Human HCC cell line, wt of SK-Hep1 cell line was kindly
provided by Dr Ralph A Reisfeld (The Scripps Research Institute, La Jolla,
CA, USA). WT of HepG2 was obtained from the Chinese Academy of
Sciences. SK-Hep1-Wt and HepG2-Wt cells were infected with lentivirus
carrying pLV-EF1α-Flag-TIFA-IRES-Bsd and pLV-EF1α-Flag-TIFAΔ6-IRES-Bsd
plasmids, followed by clonal selection using Blasticidin (5 μg/ml for SK-
Hep1 and HepG2) to generate polyclonal cell populations with stable
overexpression of Flag-TIFA and TIFAΔ6 (Sk-Hep1-Flag-TIFA, Sk-Hep1-Flag-
TIFAΔ6 and HepG2-Flag-TIFA, HepG2-Flag-TIFAΔ6). Alternatively, SK-Hep1-
Wt cells were infected with lentivirus carrying pLV-H1-shp53-puro or pLV-
H1-shTIFA-puro plasmid, followed by clonal selection using 1 μg/ml
puromycin to generate polyclonal cell populations with stable expression
of shp53 or shTIFA. For control purposes, SK-Hep1-Wt and HepG2-Wt were
infected with lentivirus carrying the empty vector plasmid, SK-Hep1-Wt
was infected with lentivirus carrying scrambled shRNA plasmid (see below
for sequence) and subjected to identical clone selection procedures to
generate the stable control cell lines SK-Hep1-Ctrl, HepG2-Ctrl and
SK-Hep1-SC. SK-Hep1 and HepG2 cells were maintained in Dulbecco’s
modified Eagle’s media supplemented with 10% fetal bovine serum,
100 U/ml penicillin/streptomycin and 1% nonessential amino acids.
Real-time reverse transcriptase–PCR
Total mRNAs from different cell lines were isolated by TRIzol reagent (cat.
#15596-018, Invitrogen Inc., Carlsbad, CA, USA) and reverse transcribed
into complementary DNAs with MMLV reverse transcriptase (Promega,
Madison, MI, USA). Real-time PCR was performed on Opticon (Bio-Rad,
Hercules, CA, USA) in 20 μl reaction volumes by using TransStart Green
qPCR SuperMix Kit (TransGen Biotech, Beijing, China). The 2−ΔΔCt method
was used to determine the relative mRNA folding changes. Statistical
results were averaged from three independent experiments performed in
triplicate.
Immunoblotting
Cell lysates from different cell lines were prepared with RIPA buffer in the
presence of protease inhibitor cocktails and Phosphatase Inhibitor Cocktail
2 and 3 (P8340, P5726 and P0044, Sigma-Aldrich, St Louis, MO, USA).
Protein (30 μg) was loaded onto 5–12% Tris-acrylamide gels and blotted
with antibodies that included: anti-TIFA, (cat. #ab103011 Abcam Biotech-
nology, Inc., Abcam, Hong Kong), β-actin (cat. #sc-47778, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), caspase-3 (cat. #9665, Cell Signal
Technology Inc., Danvers, MA, USA), p53 (cat. #sc-126, Santa Cruz
Biotechnology, Inc.), p-p53 (cat. #9284p, Cell Signal Technology Inc.),
caspase-8 (cat. #9496s, Cell Signal Technology Inc.) and horseradish
peroxidase-conjugated secondary antibodies. Blotting results were
detected by an ECL chemiluminescence kit (cat. #17153, Millipore, Billerica,
MA, USA).
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Figure 5. TIFA-mediated apoptosis depends on caspase activation,
but not p53 accumulation. (a) Western blot was performed to
analysis p53 activation in TIFA or TIFAΔ6 cells using specific anti-p53
and anti-phospho-p53 antibody. β-Actin was used as a loading
control. (b) The bar graph shows the result of three separate
experiments examining percentage of cell death after p53 suppres-
sion. Immunoblot detects cleaved caspase-3 expression in p53
suppressed cells using specific active/mature anti-caspase-3. β-Actin
was included as a loading control. (c) 5-Bromo-2-deoxyuridine
(BrdU)-FITC and 7-aminoactinomycin D (7-AAD) double staining was
used to analysis cell cycle with p53 silence down cells. Representa-
tive statistical result was shown. The corresponding result of ki-67
expression was measured by western blot. (d) Immunoblotting of
shCon cells (left panel) or shP53 cells (right panel) showing the
expression of p53 and p21 in cell culture (Grow), upon the addition
of Doxarubicin in plain media (1 ug) for 24 h (Dox), or control plain
media (Starve). (e) The bar graph shows the statistics result of three
separate experiments regarding percentage of cell death of SK-Hep1
TIFA cells treated with Z-VAD. Immunoblotting shows mature and
cleaved forms of caspase-8 as well as cleaved caspase-3. β-Actin was
included as a loading control. (f) BrdU-FITC and 7-AAD double
staining was used to detect cell cycle after cell treated with Z-VAD.
Representative statistics result was shown. The corresponding result
of ki-67 expression was measured by western blot. (g) Possible
model of TIFA in HCC. Reconstituting TIFA expression in HCC cell
lines promoted two independent effects; the activation of caspases
(3 and 8) possibly analogous to activation via classic complex 2
(TRADD/TRAF2) by TNFa or TLRs, as well as the induction of p53 and
cell cycle arrest.
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Flow cytometry analysis of cell cycle and apoptosis
Following culture of cells in the absence of fetal bovine serum for 12 h,
cells were ‘pulsed’ with 10mM 5-bromo-2-deoxyuridine for 24 h, and cell
cycle assay was performed by using the Cytofix/cytoperm kit (BD
Biosciences, San Jose, CA, USA) following the manufacturer’s instructions.
For apoptosis assay, apoptotic cells were stained with propidium iodide
and Annexin-V-FITC (BD Biosciences). Flow cytometry analysis was
performed by FACS Calibur cytometer (BD Biosciences), in which a
minimum of 10 000 events were recorded. Three independent assays were
conducted in such experiments and the mean values were expressed as
mean± s.d.
Tumor xenografts
Male NOD/SCID mice at 6–8 weeks of age were separated randomly into
three groups (n= 5 for each group based on minimal 30% decrease from
1 g tumors with 250 μg s.d. (standard deviation), α error of 0.05 and a β
error of 0.8). In all, 3 × 106 SK-Hep1 cells (Sk-Hep1-Flag-TIFA, Sk-Hep1-Flag-
TIFAΔ6 and SK-Hep1-Ctrl) were inoculated subcutaneously into each
mouse at right axilla. Tumor volume (mm3) was measured with calipers
two times per week and calculated by using the standard formula:
length×width2/2. The individual measuring the mice was unaware of the
identity of the group measured. Animal use complied with Nankai
University Animal Welfare Guidelines.
Immunohistochemistry
Immunostaining was performed on paraffin human HCC tissue arrays
(120 samples from cat. # BC03119, 30 samples from cat. # LV805, Alenabio
Company, Shanxi, China). Expression levels of TIFA in the tissue microarray
were scored according to the percentage of TIFA-positive cells in each liver
tissues. The images were recorded by Olympus BX51 Epi-fluorescent
microscopy under a 10× or 40× objective (Olympus Co., Tokyo, Japan).
TUNEL staining
Paraffin-embedded tissue slides were prepared from the tumor xenografts
DeadEndTM Fluorometric TUNEL System kit (Promega) was applied for
TUNEL staining. Experiment procedure was performed according to the
manuscript instruction. 4,6-Diamidino-2-phenylindole was used to stain
the nuclei, and the tissue slides were subjected to Olympus BX51
Epi-fluorescent microscopy under a 40× objective (FV1000-IX81, Olympus
Microsystems, Shanghai, China).
Statistical analysis
Values were expressed as means+s.e.m. Significance was determined by χ2
test in Supplementary Table 1, others were determined by Student’s t-test.
A value of Po0.05 was used as the criterion for statistical significance.
*Indicates significant difference with Po0.05, **indicates significant
difference with Po0.01.
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